Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammaplex in Primary Immunodeficiency Diseases
NCT00278954Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of intravenous immunoglobulin G in primary immunodeficiency disease (PID), sponsored by Bio Products Laboratory. Primary endpoint: Serious, Acute, Bacterial Infections at 12 months. Started Jan 2006; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT00278954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278954.